Britannia Life Sciences Inc (TSE:BLAB)
:BLAB
Top Page
Britannia Life Sciences Inc
(BLAB)
Select Model
Select Model
Rating:51Neutral
Price Target:
C$0.09
▲(12.50% Upside)
Action:ReiteratedDate:03/24/26
The score is held back primarily by weak financial quality and ongoing cash burn, despite a notably improved, low-leverage balance sheet. Technicals also show bearish near-term momentum (oversold RSI and negative MACD). The main offset is the very low P/E, indicating a cheap valuation based on the provided multiple.
Positive Factors
Low Leverage / Balance Sheet Strength
A materially de-levered balance sheet (debt-to-equity ≈0.01) gives Britannia durable financial flexibility to fund operations, invest in R&D, or absorb ongoing cash burn without immediate solvency pressure, lowering refinancing risk over coming months.
Negative Factors
Persistent Cash Burn
Materially negative trailing cash flows indicate ongoing cash burn. Persistent outflows raise near-term funding risk, may force dilutive capital raises or spending cuts, and constrain the company's ability to invest in growth or absorb operational shocks over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Balance Sheet Strength
A materially de-levered balance sheet (debt-to-equity ≈0.01) gives Britannia durable financial flexibility to fund operations, invest in R&D, or absorb ongoing cash burn without immediate solvency pressure, lowering refinancing risk over coming months.
Read all positive factors
Britannia Life Sciences Inc (BLAB) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$14.60M
Dividend YieldN/A
Average Volume (3M)73.07K
Price to Earnings (P/E)0.3
Beta (1Y)-1.31
Revenue Growth-3.93%
EPS Growth-575.24%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.07
Shares Outstanding162,254,330
10 Day Avg. Volume81,691
30 Day Avg. Volume73,070
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)1.93
Price to Sales (P/S)32.95
P/FCF Ratio-4.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Britannia Life Sciences Inc Business Overview & Revenue Model
Company Description
Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally. The company is based in Toronto, C...
Britannia Life Sciences Inc Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
66
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2025 | Jun 2023 | Jun 2022 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -4.33M | 369.28K | 7.57M | 6.40M | 7.30M | 1.42M |
| Gross Profit | -3.01M | 27.33K | 4.85M | 4.64M | 5.26M | 1.17M |
| EBITDA | -4.96M | -4.39M | -1.90M | 6.95M | -10.77M | -1.62M |
| Net Income | 20.49M | 7.39M | -4.77M | 5.08M | -15.46M | -157.16K |
Balance Sheet | ||||||
| Total Assets | 22.06M | 11.61M | 22.26M | 23.55M | 21.09M | 21.45M |
| Cash, Cash Equivalents and Short-Term Investments | 15.89M | 7.85M | 1.32M | 2.60M | 1.63M | 828.32K |
| Total Debt | 248.56K | 1.86M | 7.29M | 8.41M | 5.19M | 10.55M |
| Total Liabilities | 4.83M | 5.31M | 15.59M | 12.49M | 15.61M | 18.79M |
| Stockholders Equity | 17.23M | 6.30M | 2.44M | 7.02M | 1.35M | -202.32K |
Cash Flow | ||||||
| Free Cash Flow | -4.10M | -2.62M | 1.75M | 874.41K | 2.71M | -543.49K |
| Operating Cash Flow | -4.10M | -2.62M | 2.09M | 1.22M | 2.80M | -586.58K |
| Investing Cash Flow | 6.31M | 11.27M | -1.44M | -3.32M | 653.95K | -4.91M |
| Financing Cash Flow | -1.36M | -2.17M | -1.97M | 2.95M | -2.58M | 6.20M |
Britannia Life Sciences Inc Technical Analysis
Negative
0.08
Price Trends
0.10
Negative
0.09
Negative
0.08
Positive
Market Momentum
>-0.01
Positive
27.83
Positive
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLAB, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 27.83 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BLAB.
Britannia Life Sciences Inc Peers Comparison
UnderperformOutperform
Sector (51)
TSE:BLAB
Britannia Life Sciences Inc
0.09
0.02
28.57%
TSE:HEM
Hemostemix
0.07
-0.02
-27.78%
TSE:IOT
Innovotech
0.17
0.02
13.33%
TSE:SBM.H
Sirona Biochem
0.06
0.00
0.00%
TSE:GLOW
Glow LifeTech
0.06
-0.03
-31.25%
TSE:TELI
Telescope Innovations Corp
0.45
0.10
28.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.